Isis Pharmaceuticals, Inc. (ISIS) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
ISIS Pharmaceuticals (ISIS) Bullish Stance Reiterated at BMO Capital Post Q1
May 8, 2014 6:34 AM EDTBMO Capital analyst Jim Birchenough, M.D. reiterated an Outperform rating and $70 price target on ISIS Pharmaceuticals (NASDAQ: ISIS) following Q1 results and an update on key initiative. Net loss per share of ($0.27) was slightly wider than the consensus estimate of a loss of... More
Piper Jaffray Upgrades ISIS Pharmaceuticals (ISIS) to Overweight
May 6, 2014 3:22 PM EDTPiper Jaffray upgraded ISIS Pharmaceuticals (NASDAQ: ISIS) from Neutral to Overweight.
For an analyst ratings summary and ratings history on ISIS Pharmaceuticals click here. For more ratings news on ISIS Pharmaceuticals click here.
Shares of ISIS Pharmaceuticals closed at $25.60 yesterday.
... More